Bronchiectasis:

Assessment, management, prevention.

Kyle Perrin

Overview

- Risk factors
- Diagnosis
 - History
 - Examination
 - Investigations
- Approach to management
- Prevention

What is bronchiectasis?

- Irreversible dilation of the bronchial tree caused by destruction of the muscle and elastic tissue
- It is classified as an obstructive lung disease

Pathogenesis





Arch Dis Child 2005;90:737-740 doi:10.1136/adc.2004.066472

Acute paediatrics

New Zealand national incidence of bronchiectasis "too high" for a developed country

J Twiss^{1,2}, R Metcalfe², E Edwards^{1,2}, C Byrnes^{1,2}

Prevalence

- An overall incidence of 3.7 per 100 000 under 15 years
 - NZ European1.5
 - Maori children 4.8
 - Pacific children 17.8
- 7 times higher than Finland
- The median age at diagnosis was 5.2 years; the majority had symptoms for more than two years
- Mean FEV1 of 77% predicted

Risk factors

- Recurrent chest infections
 - Especially whooping cough
- Foreign body
- Congenital or acquired immune deficiency
- Congenital problems of cilia function

History

- Previous
 - Frequent childhood infections?
 - Other infections? (sinus, skin)

• Current

- Recurrent chest infections
- Chronic production of purulent sputum
- Haemoptysis
- Wheeze
- Breathlessness

Examination

- Sometimes finger clubbing
- Hyperinflation (in severe disease)
- Thick/coarse crackles
- Occasional wheeze

Investigations

- Spirometry
 - Obstructive, but may be normal
- CXR and CT scan
- Blood tests (immune deficiency?)
- Sputum test
- Test for CF?







Goals of treatment

- The treatment goals in adults are to
 - Control symptoms
 - Enhance quality of life
 - Reduce exacerbations
 - Maintain pulmonary function



 There is clear evidence that patients with bronchiectasis who have more frequent exacerbations have worse quality of life and worse prognosis

Treatment

- 1. Education
- 2. Treatment of the specific underlying cause
- 3. Airway clearance
 - Physiotherapy and exercise
 - Inhaled therapies

Treatment

4. Airway drug therapy

- Bronchodilation
- Anti-inflammatory
- 5. Antibiotic therapy
- 6. Surgical management
- 7. Management of complications

Airway clearance

- All patients with a productive cough should be taught airway clearance by a physiotherapist
 - Active cycle of breathing techniques
 - Postural drainage
 - Positive expiratory pressure (PEP)
 - Acapella
- Duration?
- Frequency?

Inhaled drug therapy

- Mucolytics
 - Pulmozyme (only effective in CF)
 - Mannitol
 - Hypertonic saline
- Bronchodilators
- Inhaled corticosteroids

Long term antibiotics

- Nebulised tobramycin
- Oral azithromycin

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial

Conroy Wong, Lata Jayaram, Noel Karalus, Tam Eaton, Cecilia Tong, Hans Hockey, David Milne, Wendy Fergusson, Christine Tuffery, Paul Sexton, Louanne Storey, Toni Ashton



Figure 2: Proportion of participants free from event-based exacerbations Shaded areas indicate 95% CIs. Crosses indicate censoring.

Exacerbations



Need for admission

- Unable to cope at home
- Hypoxia or confusion
- Breathlessness with respiratory rate ≥25/min
- Respiratory failure
- Temperature \geq 38 C
- Unable to take oral therapy

Antibiotics for exacerbations

- If possible guided by previous sputum results
- Common bacteria include
 - H influenzae, M catarrhalis, S aureus and S pneumoniae
 - Some patients become colonised by pseudomonas
- If no sputum culture available
 - Send a sputum sample first!
 - Augmentin or amoxicillin is a reasonable first choice
 - Modify if necessary

Other treatments

- Nutrition
- Vaccinations
- Pulmonary rehabilitation
- Surgery
- Lung transplant



Hannah age 16

- Asthma and eczema since age 3
- Whooping cough infection age 6
- Last 3-4 years had recurrent chest infections and always coughs up green sputum
- Off school a lot
- CT scan confirmed bronchiectasis

Current medications

- Seretide 2 puffs bd
- Lotatadine 10mg od
- Montelucast 10mg od
- Flixonase 2 puffs bd
- Theophyline 250mg od

Social history

- Lives in a private rental house with mum, aunty and 4 other kids
 - No insulation
 - Damp
 - A bit of mold around
- Mum works as a cleaner
- Cant afford to heat the house very often

Prevention of bronchiectasis

How do you avoid it in NZ?

Why is this important?

- Bronchiectasis is a disease of poverty and a marker of social deprivation
- Like rheumatic fever, it is a "ticking time bomb"

Why is this important?

- It often starts in childhood but the worst effects are seen in adulthood
 - Frequent hospital admissions
 - Poor quality of life
 - Early death



Hospitalisations by ethnic group, 2013



Mortality by ethnic group



Hospitalisations by deprivation, 2013



Why such a concern in NZ? comparative data

| At diagnosis | Australia | Alaska | NZ |
|-----------------------|--------------|------------|------------|
| Bilateral disease | 15.3% 50% | 38% 57% | 83% 87% |
| Widespread disease | | | 64% |

Munro K, Current Paeds 2009

Cass Byrnes ARFNZ conference 2015

What to look out for?

- Cough persistent, recurrent, wet
- Recurrent resp infections
- Hospital admissions for LRTI
- Recurrent antibx use
- School absenteeism
- SOB with sport
- Asthma poorly responsive
- Growth



Don't wait!

Cass Byrnes ARFNZ conference 2015

2003 (14 month female)



2008













Priorities

 The current approach to treatment of existing bronchiectasis patients has not changed a great deal in decades

 We <u>must</u> take steps to reduce the incidence of this condition by addressing the social determinants of health particularly among Maori and Pacifica

Priorities

- Housing
- Income inequality
- Access to primary care
- Health literacy
- Smokefree Aotearoa 2025